Multiple pathways to allograft rejection

Transplantation

Volumn 73, Issue 9, 2002, Pages 1373-1381

  Le Moine, Alain ^a   Goldman, Michel ^a   Abramowicz, Daniel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY;

ALLOIMMUNITY; ANTIBODY PRODUCTION; CELL ADHESION; CELL CONTACT; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOCYTE; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0037093372     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200205150-00001     Document Type: Review

References (108)

1. The molecular basis of allorecognition
2. HLA DNA typing and transplantation
3. The alloresponse
4. T cell receptor repertoire usage in allotransplantation: An overview
5. Minor transplantation antigens: Animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions
6. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: No requirement for CD8+ T cells or B cells
7. Acute rejection in the absence of cognate recognition of allograft by T cells
8. Dendritic cells in transplantation: Friend or foe?
9. Intramolecular and intermolecular spreading during the course of organ allograft rejection
10. Direct and indirect recognition: The role of MHC antigens in graft rejection
11. Graft tolerance: A duel of two signals
12. T cell co-stimulatory molecules other than CD28
13. Induction of Th1 and Th2 CD4+ T cell response: The alternative approaches
14. The many roles of CD40 in cell-mediated inflammatory responses
15. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
16. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
17. Isolation and characterization of dendritic cells from mouse heart and kidney
18. Dendritic cells and the control of immunity
19. Migration and maturation of Langerhans cells in skin transplants and explants
20. Immunologic ignorance of vascularized organ transplants in the absence of secondary lymphoid tissue
21. T-cell growth factors in allograft rejection and tolerance
22. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival
23. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival
24. CD4+ but not CD8+ cells are essential for allorejection
25. Interferon gamma signaling alters the function of T helper type 1 cells
26. Interferon-gamma stabilizes the T helper cell type 1 phenotype
27. Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation
28. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages
29. Dendritic cell lineage, plasticity and cross-regulation
30. Dendritic cell regulation of Th1-Th2 development
31. CD8alpha+ and CD8alpha - Subclasses of dendritic cells direct the development of distinct T helper cells in vivo
32. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection
33. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: Regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma
34. Immune responses of IL-4, IL-5, IL-6 deficient mice
35. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection
36. Differential effects of IL-12 receptor blockade with IL- 12 p40 homodimer on the induction of CD4+ and CD8+ IFN-γ-producing cells
37. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity
38. Chemokines and their receptors in allograft rejection
39. Understanding dendritic cell and T lymphocyte traffic through the analysis of chemokine receptor expression
40. Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process?
41. Chemokines, chemokine receptors, and allograft rejection
42. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock
43. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1
44. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-γ-induced chemokine Mig
45. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility-disparate skin grafts
46. Requirement of the chemokine receptor CXCR3 for acute allograft rejection
47. Donor-derived IP-10 initiates development of acute allograft rejection
48. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
49. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection
50. How do lymphocytes kill tumor cells?
51. The CTL's kiss of death
52. How do cytotoxic lymphocytes kill their targets?
53. Granzyme B-induced loss of mitochondrial inner membrane potential and cytochrome c release are caspase independent
54. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells
55. Acute rejection of vascular heart allografts by perforin-deficient mice
56. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation
57. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo
58. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
59. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells
60. Inhibition of Fas death signals by FLIPs
61. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice
62. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease
63. Cytotoxic pathways in the skin allograft rejection by CD4+ T cells
64. The role of the perforin and Fas pathways of cytotoxicity in skin graft rejection
65. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts
66. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients
67. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism
68. TRAIL: A molecule with multiple receptors and control mechanisms
69. How do cytotoxic lymphocytes kill their targets?
70. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts
71. Complement in organ transplantation. Contributions to inflammation, injury, and rejection
72. Innate immune responses to transplants: A significant variable with cadaver donors
73. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat
74. The cellular basis of cardiac allograft rejection: VIII. Mechanisms underlying delayed allograft rejection in PVG C6-deficient rats
75. CD4+ T cell-mediated rejection of major histocompatibility complex class I-disparate grafts: A role for alloantibody
76. T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity
77. Contribution of donor-specific antibodies to acute allograft rejection: Evidence from B cell-deficient mice
78. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection
79. Specific B cell tolerance is induced by cyclosporin A plus donor-specific blood transfusion pretreatment: Prolonged survival of MHC class I disparate cardiac allografts
80. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice
81. Adoptively transferred CD4+ lymphocytes from CD8-/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts
82. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages
83. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase
84. IL-5-deficient mice have a developmental defect in CD5 + B- 1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses
85. Interleukin-5 deficiency abolishes eosinophilia, airway hyperreactivity, and lung damage in a mouse asthma model
86. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13
87. IL-4 and IL- 13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts
88. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways
89. Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells
90. Eotaxin: From an eosinophilic chemokine to a major regulator of allergic reactions
91. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells
92. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo
93. Hypereosinophilic syndromes
94. Eosinophils generate brominating oxidants in allergen-induced asthma
95. Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection
96. Heterogeneity of T cell clones specific for a single indirect alloantigenic epitope (I-Ab/H-2Kd54-68) that mediate transplant rejection
97. Interleukin-2 and interferon-gamma double knockout mice reject heterotopic cardiac allografts
98. Islet allograft rejection can be mediated by CD4+, alloantigen experienced, direct pathway T cells of TH1 and TH2 cytokine phenotype
99. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection
100. Cellular basis of skin allograft rejection: An in vivo model of immune-mediated tissue destruction
101. Reactivity of hybridomas derived from T cells activated in vivo during graft versus host disease
102. The eosinophil as an effector cell of the immune response during hepatic allograft rejection
103. Evidence for a nonclassical pathway of graft rejection involving interleukin-5 and eosinophils
104. Elevated biliary interleukin-5 as an indicator of liver allograft rejection
105. Association between blood eosinophil counts and acute cardiac and pulmonary allograft rejection
106. Eosinophil cationic protein's role in human hepatic allograft rejection
107. Eosinophil granule major basic protein in acute renal allograft rejection
108. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Thland Th2 responses in vivo